Increased levels of glutamate in the central nervous system are associated with behavioral symptoms in experimental malaria

Increased levels of glutamate in the central nervous system are associated with behavioral symptoms in experimental malaria

A.S. Miranda\textsuperscript{1}, L.B. Vieira\textsuperscript{3}, N. Lacerda-Queiroz\textsuperscript{1}, A.H. Souza\textsuperscript{3}, D.H. Rodrigues\textsuperscript{1}, M.C. Vilela\textsuperscript{1}, M.V. Gomez\textsuperscript{3}, F.S. Machado\textsuperscript{2}, M.A. Rachid\textsuperscript{1} and A.L. Teixeira\textsuperscript{1}

\textsuperscript{1}Laboratório de Imunofarmacologia, \textsuperscript{2}Laboratório de Imunorregulação de Doenças Infecciosas, Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil
\textsuperscript{3}Laboratório de Medicina Molecular (INCT), Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brasil

Abstract

Cerebral malaria (CM) is a severe complication resulting from \textit{Plasmodium falciparum} infection. This condition has been associated with cognitive, behavioral and motor dysfunctions, seizures and coma. The underlying mechanisms of CM are incompletely understood. Glutamate and other metabolites such as lactate have been implicated in its pathogenesis. In the present study, we investigated the involvement of glutamate in the behavioral symptoms of CM. Seventeen female C57BL/6 mice (20-25 g) aged 6-8 weeks were infected with \textit{P. berghei} ANKA by the intraperitoneal route using a standardized inoculation of 10\textsuperscript{6} parasitized red blood cells suspended in 0.2 mL PBS. Control animals (N = 17) received the same volume of PBS. Behavioral and neurological symptoms were analyzed by the SmithKline/Harwell/Imperial College/Royal Hospital/Phenotype Assessment (SHIRPA) battery. Glutamate release was measured in the cerebral cortex and cerebrospinal fluid of infected and control mice by fluorimetric assay. All functional categories of the SHIRPA battery were significantly altered in the infected mice at 6 days post-infection (dpi) (P ≤ 0.05). In parallel to CM symptoms, we found a significant increase in glutamate levels in the cerebral cortex (mean ± SEM; control: 11.62 ± 0.90 nmol/mg protein; infected at 3 dpi: 10.36 ± 1.17 nmol/mg protein; infected at 6 dpi: 26.65 ± 0.73 nmol/mg protein; with EGTA, control: 5.60 ± 1.92 nmol/mg protein; infected at 3 dpi: 6.24 ± 1.87 nmol/mg protein; infected at 6 dpi: 14.14 ± 0.84 nmol/mg protein) and in the cerebrospinal fluid (control: 128 ± 51.23 pmol/mg protein; infected: 301.4 ± 22.52 pmol/mg protein) of infected mice (P ≤ 0.05). These findings suggest a role of glutamate in the central nervous system dysfunction found in CM.

Key words: Cerebral malaria; Glutamate; Cerebrospinal fluid; Behavioral changes; SHIRPA

Introduction

Cerebral malaria (CM) is a severe complication resulting from \textit{Plasmodium falciparum} infection (1). This condition is associated with at least 2.3 million deaths per year out of an estimated 400 million cases of malaria occurring each year worldwide (2).

According to WHO criteria, CM is a clinical syndrome defined as a potentially reversible diffuse encephalopathy characterized mainly by coma and the presence of asexual forms of \textit{P. falciparum} parasites in peripheral blood smears in the absence of other causes of encephalopathy (3). This condition can cause a wide range of clinical manifestations including cognitive, behavioral and motor dysfunctions, seizures and coma (1).

The underlying mechanisms of CM have been extensively investigated. However, the pathogenesis of CM is incompletely understood (4). One of the major hypotheses is the sequestration of parasitized red blood cells in the cerebral microvascular endothelium leading to blood flow obstruction and decreased tissue perfusion, thereby compromising the function of the central nervous system (CNS) (1).

Glutamate is the major excitatory neurotransmitter in...
the mammalian CNS, playing an important role in neuronal development, synaptic plasticity, learning and memory processes under physiological conditions (5). However, high amounts of glutamate release in intersynaptic spaces can cause neuronal cell death and neurodegeneration via excitotoxicity processes (6). Excitotoxicity plays an important role in many CNS diseases, including ischemia, trauma, and neurodegenerative disorders (7). Based on the concept that CM can be regarded as an ischemic disorder, some studies have implicated glutamate and other metabolites such as lactate, alanine and glycine in its pathogenesis (8-10). However, these studies did not evaluate the role of glutamate release and its association with CNS dysfunction in CM.

In the present study, we determined the involvement of glutamate in the behavioral symptoms occurring in CM. We analyzed behavioral and neurological symptoms, Ca^{2+}-independent and -dependent glutamate release in the cerebral cortex and glutamate levels in the cerebrospinal fluid (CSF) of C57BL/6 mice infected with P. berghei ANKA (PbA).

**Material and Methods**

**Animals**

Thirty-four female C57BL/6 mice (20-25 g) aged 6-8 weeks were obtained from the Animal Care Facilities of the Federal University of Minas Gerais, Brazil. The animals were housed in cages in temperature-controlled rooms and received food and water ad libitum. All procedures described had prior approval from the Animal Ethics Committee (CETERA) of the Federal University of Minas Gerais (UFMG) under license number 105/09.

**Parasites and experimental infection**

An uncloned parasite line of P. berghei (strain ANKA) (PbA) was used. P. berghei ANKA-parasitized red blood cells (pRBC) from C57BL/6 mouse donor strains were maintained in stabilized liquid nitrogen, thawed and passed into normal C57BL/6 mice that later served as parasite donors. C57BL/6 mice were infected by intraperitoneal (i.p.) injection of 10^6 pRBC suspended in 0.2 mL PBS (11). Control animals received the same volume of PBS. The level of parasitemia of infected mice was monitored on Giemsa-stained blood films from day 3 onwards and estimated by counting at least 1000 RBCs under oil immersion.

**SHIRPA screen**

Behavioral and functional parameters were evaluated using a screening battery called SmithKline/Harwell/Imperial College/Royal Hospital/Phenotype Assessment (SHIRPA) until the 6th day post-infection (dpi). The procedure was carried out at 0 (day of infection) and then from day 3 until death on a daily basis. The SHIRPA screen was conceived as a multi-test behavioral battery used for longitudinal studies with standardized guidelines and materials (12). This battery encompasses 40 tests, which provide a behavioral and functional profile. For analysis purposes, these individual parameters assessed by SHIRPA were organized into five functional categories: neuropsychiatric state (spontaneous activity, transfer arousal, touch escape, positional passivity, biting, fear, irritability, aggression, vocals); motor behavior (body position, tremor, locomotor activity, pelvic elevation, gait, tail elevation, trunk curl, limb grasping, wire maneuver, negative geotaxis); reflex and sensory function (startle response, visual placing, pinna reflex, corneal reflex, toe pinch, righting reflex); autonomous function (respiration rate, defecation, urination, palpebral closure, piloerection, skin color, heart rate, lacrimation, salivation, body temperature); muscle tone and strength (grip strength, body tone, limb tone, abdominal tone) and an overall score was obtained as described by Lackner et al. (13). Animals were allowed to habituate to their new environment for 2 days before behavioral assessment. A total of 8 animals per group were used in this procedure.

**Glutamate release and measurement in the cerebral cortex**

Synaptosomes were prepared as previously described (14). Mice were decapitated and their cortices were removed and homogenized in 1:10 (w/v) 0.32 M sucrose containing 0.25 mM dithiothreitol and 1 mM EDTA. Homogenates were then submitted to low-speed centrifugation (1000 g/10 min) and isolated nerve terminals (synaptosomes) were purified from the supernatant by discontinuous Percoll-density gradient centrifugation (15). The synaptosomes were resuspended in 400 µL Krebs-Ringer-HEPES buffer (124 mM NaCl, 4 mM KCl, 1.2 mM MgSO_4_, 25 mM HEPES, pH 7.4), divided into 200-µL aliquots and stored on ice for later measurement of glutamate release. The glutamate release assay was performed using an RF5301PC spectrofluorimeter (Shimadzu, Japan) monitoring the increase in fluorescence due to the production of NADPH+ in the presence of glutamate dehydrogenase and NADP+ (16). Glutamate release was measured in the cerebral cortex of PbA-infected mice at 3 and 6 dpi and of control mice. A total of 9 animals per group were used.

**Measurements of glutamate levels in the cerebrospinal fluid**

Glutamate levels were measured in the CSF of PbA-infected mice at 6 dpi and of control mice. Briefly, the mice were killed with halothane and placed in a stereotoxic apparatus, where the CSF was carefully removed (10 µL per mouse) with an insulin syringe (27 gauge x 1/2 in length), using the cisterna magna puncture technique. All samples were centrifuged at 10,000 g in an Eppendorf centrifuge for 5 min to obtain cell-free supernatants and were immediately analyzed with a spectrofluorimeter. Glutamate measurement was performed enzymatically according...
to the increase in fluorescence due to the production of NADPH in the presence of glutamate dehydrogenase and NADP+ (16). To start the assay, 1.0 mM NADP+ and 50 U glutamate dehydrogenase were added to the CSF samples 10 min after the measurement of emitted fluorescence (14). The excitation wavelength was 360 nm and the emission wavelength was 450 nm using a PTI spectrofluorimeter. Nine animals per group were used to quantify the levels of glutamate in the CSF. At least three independent experiments were performed and three samples of the CSF were analyzed in each group. The samples were obtained from the same animals used for glutamate measurements in the cerebral cortex.

Statistical analysis

One-way analysis of variance (ANOVA) with the Tukey multiple comparison post-test was used to analyze the behavioral and functional categories of SHIRPA and the brain cortical glutamate release. The unpaired Student t-test was used to analyze glutamate levels in the CSF. All analyses were performed using the Prism 4 software (GraphPad, USA).

Results

The SHIRPA battery was used to evaluate the behavioral changes of infected mice at 3 and 6 dpi. No difference was found between infected mice and controls at 3 dpi. However, all functional categories of the SHIRPA battery were significantly altered in infected mice at 6 dpi compared to the control group. When the infected mice were compared at 6 dpi to the infected mice at 3 dpi, a progressive impairment of autonomous function, neuropsychiatric state, motor behavior and muscle tone and strength was observed (Figure 1).

Since abnormal glutamatergic neurotransmission has been implicated in a wide range of neurological diseases, we measured glutamate release from isolated brain cortical nerve terminals (synaptosomes) in this CM model. No difference was found between infected mice at 3 dpi and controls. We observed that glutamate release was significantly increased in the infected mice at 6 dpi in comparison with both infected mice at 3 dpi and control animals (Figure 2). Synaptosomes from control animals were exposed to 33 mM KCl to depolarize their membranes and induce glutamate release (Figure 2). KCl-evoked glutamate release from synaptosomes obtained from infected mice at 6 dpi was approximately 3-fold higher than that observed in control animals (Figure 2; P ≤ 0.05).

When synaptosomes were depolarized with KCl, the release of glutamate was the sum of two components: one that is extracellular calcium dependent and inhibited by the calcium chelator EGTA, and the other, which is extracellular calcium independent and not sensitive to EGTA. We therefore measured KCl-evoked glutamate release in infected mice at 3 and 6 dpi and in control synaptosomes in the presence of EGTA, which reflects the calcium-independent pool. In both situations (control and infected mice), KCl-evoked glutamate release was reduced in the presence of EGTA (Figure 2; P ≤ 0.05). Even in the presence of EGTA,
glutamate release was significantly increased in infected mice at 6 dpi compared to both infected mice at 3 dpi and controls.

We also measured CSF glutamate levels in PbA-infected mice at 6 dpi. The 6th dpi was chosen because it was the day we found the highest levels of brain glutamate associated with behavioral changes in infected mice. The glutamate levels found in the CSF of infected mice were significantly increased compared to control animals (mean ± SEM; control: 128 ± 51.23 pmol/mg protein; infected: 301.4 ± 22.52 pmol/mg protein; P ≤ 0.05. Results are representative of three independent experiments).

Discussion

We investigated behavioral symptoms in C57BL/6 mice infected with PbA using the SHIRPA screen battery. In our study, we observed progressive neurological and behavioral changes. At 6 dpi most of the SHIRPA domains were significantly altered including, neuropsychiatric state, motor behavior, reflex and sensory function, autonomous function, muscle tone and strength. In order to detect a neurochemical marker of CM, we investigated the involvement of glutamate in the development of CM. The amount of glutamate present in the cerebrocortical synaptosomes as well as in the CSF of infected mice was significantly increased at 6 dpi. Since there is a parallel increase in brain and CSF glutamate levels with the neurological symptoms of CM, this may suggest a role for glutamate in CM pathogenesis.

Animals susceptible to PbA infection such as C57BL/6 mice develop neurological and behavioral symptoms that are similar to those observed in human CM, which include ataxia, paralysis, seizures, and coma (17). In the present study, using the SHIRPA battery, we found a wide range of behavioral changes in infected mice at 6 dpi. In agreement with these findings, previous studies also described significant changes in the functional categories of the SHIRPA battery approximately 6 days after PbA infection (13,18).

The excitotoxicity process mediated by glutamate and other amino acids, such as aspartic acid and quinolinic acid that act via glutamate receptors, has been implicated in the occurrence of neurological and cognitive symptoms in CM (8-10,19,20). In the present study, we found increased glutamate release in the brain and increased levels of this neurotransmitter in the CSF of PbA-infected mice in association with behavioral changes. To the best of our knowledge, no previous study has investigated the association between increased glutamate release into intersynaptic spaces and CNS dysfunction in CM. A study performed by Rae et al. (9) demonstrated an increase of glutamate C4(γ) levels as measured by 13C nuclear magnetic resonance spectroscopy in the metabolite pool from brain extracts of PbA-infected mice at 6 dpi. We confirmed the increase of glutamate levels and demonstrated an enhanced release of glutamate in the synaptic cleft. Furthermore, studies of biochemical changes have demonstrated increased levels of quinolinic acid in the CSF of adults and children with CM, indicating a role of excitotoxic mechanisms in the pathogenesis of the disease (19,20). Parekh et al. (10) also found an increase of glutamine levels in the metabolite pool from brain extracts of PbA-infected mice. Taken together, these studies suggest that an imbalance in glutamate/glutamine metabolism may be relevant to CM pathogenesis.

In conclusion, we found that increased glutamate release is associated with neurological and behavioral symptoms in CM. These findings suggest a role for glutamate in the CNS dysfunction found in CM disease.

Acknowledgments

Research supported by CAPES, CNPq, and Rede Instituto Brasileiro de Neurociência (IBNet/FINEP), Brasil.

References


